Günümüzde, klinik olarak organa sınırlı prostat kanserinin (PCa) cerrahi tedavi seçeneği radikal prostatektomidir (RP).  Radikal prostatektomide hedef hastalığın onkolojik eradikasyonunu sağlarken, yaşam kalitesinin devamlılığı için önemli olan kontinans ve erektil fonksiyonları korumaktır.  Onlarca yıl açık cerrahi teknik ile RP lokalize PCa'da standart cerrahi tedavi yöntemi olarak kabul edildi.  1991 ABSTRACT OBJECTIVE: We aimed to compare the early postoperative erectile functions of patients who underwent extraperitoneal laparascopic radical prostatectomy (eLRP) with 3-port and conventional methods for prostate cancer. MATERIAL and METHODS: We reviewed the medical records of the patients who underwent radical prostatectomy between September 2016 and October 2018 retrospectively. The patients were divided into two groups as 3-ports eLRP and conventional eLRP. International erectile function index-5 (IIEF-5) form was used preoperatively and postoperatively at the 6th month to evaluate the erectile function of the patients. Patients with IIEF-5 score >21 were considered as potent, and IIEF-5<11 was considered as severe erectile dysfunction (ED). IIEF-5 scores of preoperatively potent patients who underwent 3-port eLRP and conventional eLRP were compared at postoperative 6th month. RESULTS: In total, 92 patients who underwent eLRP were included in the study. Of these, 23 were 3-port eLRP, 69 were conventional eLRP patients. Mean age was 63.4±6.10 years, mean prostate specific antigen (PSA) was 10.7±8.55 ng/dl. There were no statistically difference between compared groups in terms of age, PSA, preoperative and postoperative Gleason score, clinical and pathological stage, neurovascular bundle protection, positive surgical margin, postoperative continence status and postoperative erectile function 6th month. CONCLUSION: The 3-port eLRP, which is similar to the conventional method in terms of oncologic, surgical and early functional results, can be preferred as a minimally invasive surgical approach in the treatment of prostate cancer by maintaining erectile functions with better cosmetic results.